Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
2.240
+0.040 (1.81%)
Dec 26, 2024, 4:00 PM EST - Market closed
Inventiva Revenue
Inventiva had revenue of 2.73M EUR in the half year ending June 30, 2024, a decrease of -19.40%. This brings the company's revenue in the last twelve months to 19.28M, down -12.56% year-over-year. In the year 2023, Inventiva had annual revenue of 23.16M with 23.12% growth.
Revenue (ttm)
19.28M EUR
Revenue Growth
-12.56%
P/S Ratio
n/a
Revenue / Employee
156,707 EUR
Employees
123
Market Cap
202.65M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 23.16M | 4.35M | 23.12% |
Dec 31, 2022 | 18.81M | 10.31M | 121.32% |
Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
Dec 31, 2019 | 11.29M | 3.91M | 53.02% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
MacroGenics | 141.33M |
Organigram Holdings | 118.32M |
Mersana Therapeutics | 34.84M |
Inhibrx Biosciences | 1.57M |
Cardiff Oncology | 688.00K |
Atai Life Sciences | 331.00K |
Inhibikase Therapeutics | 1.00 |
IVA News
- 9 days ago - Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 11 days ago - Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million - GlobeNewsWire
- 14 days ago - Results of the votes of the Combined Shareholders' General Meeting of December 11, 2024 - GlobeNewsWire
- 5 weeks ago - Inventiva reports 2024 Third Quarter Financial Information¹ - GlobeNewsWire
- 5 weeks ago - Combined General Meeting of December 11, 2024 - Availability of the preparatory documents - GlobeNewsWire
- 5 weeks ago - Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams - Business Wire
- 5 weeks ago - Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session - GlobeNewsWire
- 2 months ago - Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH - GlobeNewsWire